linjc16/ctgov huggingface dataset:
Postprandial Effects of Milk and Milk Constituents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the addition of milk or the milk constituents calcium and protein to a high-fat breakfast affects the postprandial lipid and inflammatory response.

Official Title
-----------------
The Effects of Milk and Milk Constituents on Postprandial Inflammation in Overweight Subjects

Conditions
-----------------
Hyperlipidemia, Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: Milk
* Dietary Supplement: Protein
* Dietary Supplement: Calcium
* Dietary Supplement: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index (BMI) above 27 kg/m2 Exclusion Criteria: Smoking Diabetes mellitus Cardiovascular diseases Familial hypercholesterolemia or lipid lowering medication Severe conditions that might interfere with the study outcomes, such as COPD, asthma, rheumatoid arthritis, etc. Unstable body weight Abuse of alcohol or drugs Participation in another biomedical study during the past 30 days Having donated blood during the past 30 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Milk<br>500 mL low-fat milk added to high-fat meal | Dietary Supplement: Milk<br>* 500 mL low-fat milk added to high-fat meal<br>|
| Experimental: Protein<br>Milk protein in 500 mL water added to high-fat meal | Dietary Supplement: Protein<br>* Milk protein in 500 mL water added to high-fat meal<br>|
| Experimental: Calcium<br>Milk calcium in 500 mL water added to high-fat meal | Dietary Supplement: Calcium<br>* Milk calcium in 500 mL water added to high-fat meal<br>|
| Experimental: Control<br>Lactose in 500 mL water added to high-fat meal (control condition) | Dietary Supplement: Control<br>* Lactose in 500 mL water added to high-fat meal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma inflammatory markers |  | 6 h after meal | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum lipids |  | 6 h after meal | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Milk, Postprandial hyperlipidemia, Postprandial inflammation, Overweight
Usefulness of Coronary Computed Tomography Angiography for Therapeutic Decision- Making; Revascularization

Study Overview
=================
Brief Summary
-----------------
As the prospective, observational, cross-sectional study, the accuracy of CT angiography-based therapeutic decision-making for revascularization will be evaluated. The primary objective of this study is to evaluate the accuracy of CT angiography-based therapeutic decision-making for revascularization prior to conventional angiography whether CT angiography is an accurate non-invasive technique to determine the most appropriate therapeutic strategies.

Conditions
-----------------
Coronary Artery Disease, Ischemic Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients ≥ 20 years old Patients who are scheduled for elective conventional coronary angiography and are undergone CT angiography prior to conventional coronary angiography. Exclusion Criteria: Pregnant women or women with potential childbearing

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of CT angiography | Sensitivity, specificity, positive predictive value, and negative predictive value for revascularization including PCI and CABG. | 1day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Coronary CT angiography; Revascularization; Decision-making
Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if there are significant differences in the side effects related to memory, repetition and recall among these three drugs when used in a pediatric population.

Official Title
-----------------
Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine

Conditions
-----------------
Migraine

Intervention / Treatment
-----------------
* Drug: propranolol
* Drug: zonisamide
* Drug: topiramate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of migraine with and without aura or chronic daily headache as defined by IHS subjects must between the age of 8-17 (inclusive) Exclusion Criteria: diagnosis of tension-type headache or cluster headache

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: propranolol<br>* standard pediatric doses, based on body weight<br>* Other names: Inderal;|
| Active Comparator: 2<br> | Drug: zonisamide<br>* standard pediatric dosages, based on body weight<br>* Other names: Zonegran;|
| Active Comparator: 3<br> | Drug: topiramate<br>* standard pediatric dosages, based on body weight<br>* Other names: Topamax;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Record if memory, repetition or recall was impaired by subject during specific time frame on medication. |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
migraine
Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic

Study Overview
=================
Brief Summary
-----------------
The long-term goal for this study is to improve compliance of screening for diabetic retinopathy among subjects with diabetes. Researchers are also doing this research to determine the ability of appropriately trained family physicians to screen for and identify Diabetic Retinopathy using a retinal camera in addition to determining an overall patient perspective of the convenience and cost-effectiveness of retinal imaging within a primary care setting.

Official Title
-----------------
A Pilot Study to Assess Screening for Diabetic Retinopathy Using Retinal Camera in Family Medicine Clinic

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Other: Screening eye exam using Optos technology


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient ≥ 18 years of age Diabetes Mellitus Type I or II Patient is willing and able to provide informed written consent Exclusion Criteria: • Known Diabetic Retinopathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Single Arm Trial<br>Intervention includes screening eye exam using Optos technology | Other: Screening eye exam using Optos technology<br>* Retinal imaging using Optos technology to identify Diabetic Retinopathy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Family Physicians Screening for Diabetic Retinopathy - Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist | Number of photographs that are interpreted accurately by the family physicians when compared to the retinal specialist. These photographs are obtained using retinal imaging and after the initial read by the family physicians trained to interpret the images, the images will be reviewed by the retinal specialist to determine if the interpreted results are accurate. | 6 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Screening Impact - Percentage increase in the screening rates for Diabetic Retinopathy using retinal imaging. | Percentage increase in the screening rates for Diabetic Retinopathy using retinal imaging using OPTOS when compared with the traditional dilated eye exam.The current screening rate is around 55%. | 6 months |
Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting

Study Overview
=================
Brief Summary
-----------------
phase II randomized, double-blind, placebo-controlled trial to investigate whether pregabalin can improve the complete control of nausea and vomiting (primary end point)

Detailed Description
-----------------
chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic chemotherapy. All patients will receive IV ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg, bd, on days 2 and 3. Patients will be randomly assigned to take pregabalin 75 mg or placebo, bd, from the night before chemotherapy to day 5.

Official Title
-----------------
Phase II Study of Pregabalin for the Prevention of Chemotherapy Induced Nausea and Vomiting

Conditions
-----------------
Nausea

Intervention / Treatment
-----------------
* Drug: Pregabalin
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled to receive their first cycle of moderately to highly emetogenic chemotherapy; 18 years or older; Eastern Cooperative Oncology Group < 2 Exclusion Criteria: Nausea or vomiting 24h before randomization aspartate aminotransferase / alanine aminotransferase above 3 times the upper limit Severe cognitive compromise; regular use of corticosteroids, opioid, benzodiazepines, tricyclic antidepressant, or cannabinoids within 30 days before randomization; brain metastasis; chronic alcoholism;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: chemotherapy-naive patients, scheduled to receive moderately and highly emetogenic chemotherapy will be randomized for two arms: pregabalin and placebo. All patients received will receive IV ondansetron 8 mg, dexamethasone 10 mg and ranitidine 50 mg before chemotherapy on day 1 and oral dexamethasone 4 mg, bd, on days 2 and 3.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pregabalin<br>Pregabalin 75mg, twice a day, from the night before chemotherapy to day 5 | Drug: Pregabalin<br>* antipsychotic<br>* Other names: Lyrica;|
| Experimental: Placebo<br>Placebo, twice a day, from the night before chemotherapy to day 5 | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients achieving complete control of nausea and vomiting |  | five days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregabalin, nausea
Dietary Intake After Laparoscopic Sleeve Gastrectomy -a 5 Year Study

Study Overview
=================
Brief Summary
-----------------
Weight reducing surgery is the only effective therapy for morbid obese patients. Sleeve gastrectomy is a popular choice for bariatric surgery because of less sequela. There is poor knowledge about the nutritional status inpatients after LSG. The aim of our study was to investigate the relationship between dietary intake and weight loss after LSG.

Detailed Description
-----------------
Weight reducing surgery is the only effective therapy for morbid obese patients. Restrictive type surgery is safer than mal-absorptive type surgery. Laparoscopic sleeve gastrectomy is an effective surgery. In laparoscopic sleeve gastrectomy (LSG), about 90% of the stomach is surgically removed by vertical resection of the great curvature side, including the fundus. The simplicity of surgical procedures, the low occurrence of complications, and the efficiency of reducing excess weight have made LSG as a popular choice for bariatric surgery. After LSG, the amount of food eaten is drastically reduced, leading to nutritional deficiencies potentially. There is poor knowledge about the nutritional status inpatients after LSG. Some literatures suggest that LSG results in less nutritional deficiencies than Roux-en-Y gastric bypass. The aim of our study was to investigate the relationship between dietary intake and weight loss after LSG.

Official Title
-----------------
Weight Loss and Metabolic Surgery Center Min-Sheng General Hospital

Conditions
-----------------
Morbid Obesity

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: morbid obesity patients received laparoscopic sleeve gastrectomy for more then 5 years. BMI above 40 kg/m2 when operation. Age 18-65 years old. No major psychosis or binge eating disorder. No endocrine disease. failed to lose weight with medical therapy. Exclusion Criteria: current hepatitis, under steroid treatment,cancer, thyroid disease,alcoholism.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dietary intake after laparoscopic sleeve gastrectomy 5 years | The aim of this study was to investigate the relationship between dietary intake and weight loss effect after sleeve gastrectomy.The calculation of the majority of the nutrients is based on Australian nutrient composition data. The item include: energy ( kcal/day), protein, fat, carbohydrate, vitamin and minerals. | up to 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleeve gastrectomy, dietary intake, morbid obesity.
Obesity Among Young Adult Males Born With Cesarean Section.

Study Overview
=================
Brief Summary
-----------------
Previous research has suggested that cesarean section may be associated with an increased risk of developing obesity in childhood, adolescence and adulthood. Yet, previous studies have been small or unable to differentiate between elective and non-elective cesarean section. Therefore, using a population-based cohort the purpose is to examine the associations between vaginal delivery, elective and non-elective cesarean section on the risk of developing obesity in young adulthood among Swedish young singleton males. Using the Swedish medical birth registry, the recorded mode of delivery and indication of delivery which will be matched to those males who perform military conscription, where their body mass index is recorded. The investigators hypothesize that there will be an elevated risk of obesity in those born with non-elective cesarean section, as a function of confounding, while those born with elective cesarean section will not have a higher risk of obesity than those born with vaginal delivery.

Official Title
-----------------
Elective and Non-elective Cesarean Section and the Risk for Obesity Among Young Male Conscripts: a Population-based Cohort and Matched-sibling Analysis.

Conditions
-----------------
Obesity, Caesarean Section, Cesarean Section Complications

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Singleton birth. Retrievable from medical birth registry. Exclusion Criteria: No available information on mode of delivery. Not conscripted. Extreme values at conscription.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Categories of body mass index | World health organisation categories of body mass index: underweight BMI<18.5, normal weight BMI 18.5-24.9, overweight BMI 25-29.9 and obese BMI>30. Weight at conscription was measured using standardized scales and height was assessed using stadiometers in a standardized manner. | Measured at conscription ( 18 years of age) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continuous body mass index | Measured continuous body mass index | Measured at conscription ( 18 years of age) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Cesarean Section, Vaginal Delivery, Elective Cesarean Section, Non-elective Cesarean Section
Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women

Study Overview
=================
Brief Summary
-----------------
Characterization of the uterine microbiome in women with repeated implantation failure as well as in normal fertile women.

Detailed Description
-----------------
In the midluteal phase of the cycle, a vaginal swab and endometrial biopsy will be obtained.

Official Title
-----------------
Comparative Analysis of the Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women

Conditions
-----------------
Repeated Implantation Failure, Normal Fertile

Intervention / Treatment
-----------------
* Other: Vaginal swab + endometrial biopsy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women between their 18th and 40th birthdays (max 39 years and 364 days at the day of signing the informed consent) Able to understand, read and speak Dutch and hence to provide written and oral informed consent Negative serological tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), Rapid plasma reagin (RPR) for syphilis Exclusion Criteria: Hormonal contraception in current cycle Presence of intra-uterine device Antibiotic treatment in the current cycle

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| RIF (women with repeated implantation failure)<br>Transfer of at least 5 good quality embryos in IVF or ICSI cycles, without achieving pregnancy | Other: Vaginal swab + endometrial biopsy<br>* In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.<br>|
| NF (normal fertile women)<br>Spontaneous conception or conception after max 9 IUI cycles | Other: Vaginal swab + endometrial biopsy<br>* In the midluteal phase of the cycle, a vaginal swab (E swab) and endometrial biopsy (TAO brush) will be obtained.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Midluteal uterine microbiome profile | Descriptive analysis of the uterine microbiome present | 1 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Midluteal vaginal microbiome profile | Descriptive analysis of the vaginal microbiome present (quality control of endometrial sampling) | 1 week |
Reproducibility of an Immobilization Device (BodyFIX) - Hodgkins/Lymphoma

Study Overview
=================
Brief Summary
-----------------
Radiation therapy has a well-established role in the treatment of Hodgkin's Disease and non-Hodgkin's Lymphoma. With technological developments, 3-D Dimensional (3D) planning has evolved as a highly precise treatment planning option. High-precision radiation therapy has the potential for more accurate dose delivery to the tumour volume and can result in a greater sparing of normal tissue. An important component of safe radiotherapy delivery is the feasibility and reproducibility of current and new immobilization devices for highly conformal treatment. The purpose of this study is to determine the reproducibility of an immobilization device known as BodyFIX(TM) using conventional treatment techniques.

Official Title
-----------------
A Study to Examine the Reproducibility of an Immobilization Device (BodyFIX ) to Deliver High Precision Radiation Therapy for Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma

Conditions
-----------------
Hodgkin's Disease, Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Device: BodyFIX


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients undergoing curative or palliative treatment in whom it is considered that immobilization of part or all of an anatomical region would be of benefit to their care. Exclusion Criteria: Any case where ideal treatment may be compromised with use of immobilization method. If the patient has any social issues, language barriers resulting in difficulties comprehending the nature of the study, or poor performance status, that could compromise compliance with the study guidelines.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: BodyFIX|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary outcome for the study is the average deviation in set-up. |  |  |